Even more relevant would be the extensive characterization of the intrinsically and acquired cetuximab-resistant CRC cell lines in order to verify the expression of different markers and signaling pathways, such as MET activation [38], which will provide essential information for the identification of cetuximab resistance mechanisms in CRC. The gene discussed is MET; the disease is colorectal carcinoma.